Premature ovarian insufficiency (POI)—formerly called premature ovarian failure—is cessation of ovarian hormone production and egg release before age 40, affecting approximately 1 in 100 women.
Premature ovarian insufficiency (POI)—formerly called premature ovarian failure—is cessation of ovarian hormone production and egg release before age 40, affecting approximately 1 in 100 women. Causes include genetic mutations (e.g., FMR1), autoimmune attack on follicles, chemotherapy or radiation damage, infection, or idiopathic (unknown) depletion of the primordial follicle pool. The result is infertility, oestrogen deficiency, and systemic menopausal symptoms despite young age. Current treatment is hormone replacement; fertility restoration is limited. Placental MSCs and fetal stem cells are being explored to regenerate follicle development or restore ovarian hormone production through direct cellular replacement, growth-factor secretion, and immunomodulation (suppressing anti-ovarian autoimmunity). Transplantation of cells into the ovary or systemic infusion aims to stimulate dormant follicles or create a regenerative microenvironment.
| 指示性成本 · 保加利亚 (EU) | €3,000–€8,000 |
|---|---|
| 全球市场成本范围 | €6,440–€23,000 (placidway.com) |
| 研究的主要细胞类型 | MSCs from Amniotic Membrane, Fetal Stem Cells |
| 批准状态 | 研究性 |
| 注册的临床试验 (ClinicalTrials.gov) | 35 · 3 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Thirty-five completed trials and 3 actively recruiting trials are registered for POI cell therapy, predominantly using autologous or allogeneic placental MSCs and fetal-derived cell preparations. Trial designs vary from direct ovarian injection to systemic intravenous infusion. Outcomes tracked include restored menstruation, improved hormone levels (oestradiol, FSH), pregnancy achievement, and ultrasound evidence of follicle development. Approximately 30–50% of treated women report return of menstrual cycles within 3–6 months; pregnancy rates (per cycle or per treatment) vary widely (10–40% in published small series) and are confounded by concurrent fertility treatments (in-vitro fertilisation, egg freezing).
Depending on assessment, a Premature Ovarian Insufficiency protocol may draw on:
POI cell therapy costs €4,500–8,000 per treatment, often requiring two to three infusions over a 6-month period. Additional fertility workup (hormone panel, ovarian ultrasound, sometimes egg retrieval and banking) adds €2,500–5,000. If fertility restoration is the goal, concurrent in-vitro fertilisation (IVF) can add €8,000–15,000, making total investment in combined POI cell therapy and fertility treatment €20,000–40,000 or more.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Premature Ovarian Insufficiency cost-by-country breakdown, or compare the best countries for Premature Ovarian Insufficiency →
Before booking, check safety & regulation, the recovery climate, 您是否可能是候选人, and which cell type fits Premature Ovarian Insufficiency.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: 我是候选人吗？ · 哪种细胞类型？ · Types of clinics & best countries · 成本计算器
由 StemCellAtlas 的编辑团队进行医学审查，与Dr Dmytro Stoyanov (Urologist · 31+ yrs clinical practice) 合作诊所 Stem Plus（索菲亚）的，根据 ISSCR、FDA 和 EMA 指南。 Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估